Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarth… Read more
Zeo ScientifiX, Inc. (ZEOX) - Net Assets
Latest net assets as of October 2025: $-1.42 Million USD
Based on the latest financial reports, Zeo ScientifiX, Inc. (ZEOX) has net assets worth $-1.42 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.53 Million) and total liabilities ($2.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.42 Million |
| % of Total Assets | -93.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Zeo ScientifiX, Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Zeo ScientifiX, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zeo ScientifiX, Inc. (2020–2025)
The table below shows the annual net assets of Zeo ScientifiX, Inc. from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | $-1.42 Million | +13.91% |
| 2024-10-31 | $-1.65 Million | -33.20% |
| 2023-10-31 | $-1.24 Million | -165.71% |
| 2022-10-31 | $1.89 Million | +170.85% |
| 2021-10-31 | $-2.67 Million | -91.52% |
| 2020-10-31 | $-1.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zeo ScientifiX, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3886581100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $66.31 Million | % |
| Total Equity | $-1.42 Million | 100.00% |
Zeo ScientifiX, Inc. Competitors by Market Cap
The table below lists competitors of Zeo ScientifiX, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cloudastructure, Inc. Class A Common Stock
NASDAQ:CSAI
|
$10.59 Million |
|
Remsons Industries Limited
NSE:REMSONSIND
|
$10.60 Million |
|
Rapid Dose Therapeutics Corp
PINK:RDTCF
|
$10.60 Million |
|
The Investment Trust Of India Limited
NSE:THEINVEST
|
$10.60 Million |
|
Galileo Mining Ltd
AU:GAL
|
$10.59 Million |
|
Ion Video Ltd
AU:IOV
|
$10.59 Million |
|
Vraj Iron and Steel Ltd
NSE:VRAJ
|
$10.58 Million |
|
NORTHERN FREEGOLD
F:8N6
|
$10.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zeo ScientifiX, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,653,000 to -1,423,000, a change of 230,000.
- Net loss of 5,521,000 reduced equity.
- New share issuances of 300,000 increased equity.
- Other factors increased equity by 5,451,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.52 Million | -387.98% |
| Share Issuances | $300.00K | +21.08% |
| Other Changes | $5.45 Million | +383.06% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Zeo ScientifiX, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-10-31 | $-0.30 | $2.65 | x |
| 2021-10-31 | $-0.47 | $2.65 | x |
| 2022-10-31 | $0.26 | $2.65 | x |
| 2023-10-31 | $-0.17 | $2.65 | x |
| 2024-10-31 | $-0.26 | $2.65 | x |
| 2025-10-31 | $-0.21 | $2.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zeo ScientifiX, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -106.19%
- • Asset Turnover: 3.40x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-78.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -411.78% | 2.29x | 0.00x | $-12.44 Million |
| 2021 | 0.00% | -227.90% | 2.90x | 0.00x | $-12.49 Million |
| 2022 | -471.07% | -137.06% | 1.05x | 3.28x | $-9.09 Million |
| 2023 | 0.00% | -153.29% | 1.64x | 0.00x | $-6.86 Million |
| 2024 | 0.00% | -101.84% | 2.81x | 0.00x | $-4.54 Million |
| 2025 | 0.00% | -106.19% | 3.40x | 0.00x | $-5.38 Million |
Industry Comparison
This section compares Zeo ScientifiX, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zeo ScientifiX, Inc. (ZEOX) | $-1.42 Million | 0.00% | N/A | $10.59 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |